omniture
logo
Search
基石药业（苏州）有限公司 CSTONE PHARMACEUTICALS
Media Room

Latest News

rss

CStone Pharmaceuticals Announces Updated Results from Two Studies of Its Anti-PD-L1 Monoclonal Antibody Sugemalimab (CS1001) At 2020 CSCO Annual Meeting

* CS1001-201 study demonstrated an objective response rate (ORR) of 44.7%, a complete response (C...

2020-09-25 15:28 4207

CStone Announces Preliminary Results from a Bridging Study of Avapritinib in Chinese Patients with Unresectable or Metastatic Gastrointestinal Stromal Tumors at the 2020 CSCO Annual Meeting

* Avapritinib has demonstrated strong anti-tumor activity in Chinese patients with PDGFRA D842V m...

2020-09-25 14:53 4353

CStone Receives US FDA IND Clearance for CS1001-201 Study to Evaluate Anti-PD-L1 Monoclonal Antibody Sugemalimab Monotherapy in R/R ENKTL

SUZHOU, China, Aug. 31, 2020 /PRNewswire/ -- CStone Pharmaceuticals (SUZHOU) Co., Ltd. ("CStone", H...

2020-08-31 11:35 3807

CStone Pharmaceuticals Reports Financial Results for the First Half of 2020

SUZHOU, China, Aug. 19, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616), a leadi...

2020-08-19 09:33 4545

CStone submits new drug application for the targeted therapy avapritinib in Taiwan for the treatment of adults with advanced PDGFRA exon 18 mutant gastrointestinal stromal tumor

SUZHOU, China, March 27, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HK...

2020-03-27 14:02 1603

CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination with Bayer's regorafenib

SUZHOU, China, Jan. 24, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKE...

2020-01-24 14:26 3509

CStone successfully hosted the first U.S. R&D Day in New York

* Among CStone's 15 cancer drug candidates, five candidates are in pivotal late-stage clinical de...

2020-01-24 08:18 3885

CStone successfully hosted the first U.S. R&D Day in New York

* Among CStone's 15 cancer drug candidates, five candidates are in pivotal late-stage clinical de...

2020-01-24 08:03 2573

CStone announces first patient dosed in the Phase III trial of CS1001 in combination with chemotherapy in first-line esophageal squamous cell carcinoma

SUZHOU, China, Jan. 8, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX...

2020-01-08 13:45 3093

CStone completes registration filing for the Phase I trial of its tumor immune microenvironment modulator CS3005 to enable study initiation in Australia

SUZHOU, China, Dec. 12, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKE...

2019-12-12 14:47 3324

CStone announces enrollment target reached in the global Phase III VOYAGER trial of avapritinib in Chinese patients with third-line GIST

SUZHOU, China, Dec. 11, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKE...

2019-12-11 11:00 2913

CStone's anti-PD-L1 antibody demonstrates promising antitumor activity with a complete response rate of 33.3% and a good safety profile in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma

SUZHOU, China, Dec. 10, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKE...

2019-12-10 11:38 2672

CStone appoints seasoned pharmaceutical executive Shirley Zhao as the General Manager for Greater China and Head of Commercial

SUZHOU, China, Dec. 6, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX...

2019-12-06 18:53 3779
12345